Andrew Eibl
Co-Founder

Develops a wireless, wearable Doppler ultrasound device that provides real-time hemodynamic assessments by measuring carotid arterial pulse metrics. This technology enables clinicians to optimize fluid resuscitation in critically ill patients, improving decision-making speed and accuracy in high-pressure environments like sepsis and septic shock management.
Raised to date
$38.1MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.



Co-Founder
Co-Founder
In critical care settings like sepsis and septic shock management, timely and accurate hemodynamic assessments are crucial for effective fluid resuscitation. Traditional Doppler ultrasound methods, while effective, can be delayed in high-pressure clinical environments, impacting timely decision-making.
Flosonics Medical offers FloPatch, a wireless, wearable Doppler ultrasound device that provides clinicians with real-time hemodynamic assessments. The device is worn on the patient's neck and assesses the carotid arterial pulse, offering insights into cardiac performance and fluid responsiveness. By wirelessly transmitting data to a secure mobile application, FloPatch enables clinicians to make confident, data-driven decisions, optimizing fluid resuscitation and preventing potentially harmful interventions. This technology improves patient safety and enhances care efficiency by providing a simple, fast, and consistent method for measuring changes in blood flow and heart function related to IV fluid volume.
The primary target audience includes clinicians in acute care settings, particularly those managing critically ill patients with conditions like sepsis, septic shock, and congestive heart failure, as well as emergency departments and ICUs.